X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs PANACEA BIOTECH - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. PANACEA BIOTECH FRESENIUS KABI ONCO./
PANACEA BIOTECH
 
P/E (TTM) x 22.1 -16.1 - View Chart
P/BV x 3.1 1.9 163.6% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 FRESENIUS KABI ONCO.   PANACEA BIOTECH
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
PANACEA BIOTECH
Mar-14
FRESENIUS KABI ONCO./
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs176149 118.4%   
Low Rs7982 95.4%   
Sales per share (Unadj.) Rs37.784.1 44.8%  
Earnings per share (Unadj.) Rs5.1-18.3 -27.8%  
Cash flow per share (Unadj.) Rs6.7-6.7 -100.4%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.583.7 50.8%  
Shares outstanding (eoy) m158.2361.25 258.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.4 246.0%   
Avg P/E ratio x25.0-6.3 -396.0%  
P/CF ratio (eoy) x18.9-17.2 -109.8%  
Price / Book Value ratio x3.01.4 216.8%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,1357,074 284.6%   
No. of employees `0001.22.8 41.9%   
Total wages/salary Rs m7031,449 48.5%   
Avg. sales/employee Rs Th5,176.21,874.1 276.2%   
Avg. wages/employee Rs Th610.4527.0 115.8%   
Avg. net profit/employee Rs Th699.6-407.7 -171.6%   
INCOME DATA
Net Sales Rs m5,9635,154 115.7%  
Other income Rs m18100 18.0%   
Total revenues Rs m5,9815,254 113.8%   
Gross profit Rs m1,430-766 -186.6%  
Depreciation Rs m258711 36.3%   
Interest Rs m-261,503 -1.7%   
Profit before tax Rs m1,216-2,881 -42.2%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m-681,771 -3.8%   
Tax Rs m34217 2,036.9%   
Profit after tax Rs m806-1,121 -71.9%  
Gross profit margin %24.0-14.9 -161.3%  
Effective tax rate %28.1-0.6 -4,824.3%   
Net profit margin %13.5-21.8 -62.1%  
BALANCE SHEET DATA
Current assets Rs m5,1023,810 133.9%   
Current liabilities Rs m2,3858,365 28.5%   
Net working cap to sales %45.6-88.4 -51.5%  
Current ratio x2.10.5 469.5%  
Inventory Days Days150156 96.4%  
Debtors Days Days11367 168.5%  
Net fixed assets Rs m5,14814,480 35.6%   
Share capital Rs m15861 258.1%   
"Free" reserves Rs m6,556903 725.9%   
Net worth Rs m6,7325,127 131.3%   
Long term debt Rs m9525,832 16.3%   
Total assets Rs m10,38819,433 53.5%  
Interest coverage x-45.8-0.9 4,994.8%   
Debt to equity ratio x0.11.1 12.4%  
Sales to assets ratio x0.60.3 216.5%   
Return on assets %7.52.0 382.2%  
Return on equity %12.0-21.9 -54.7%  
Return on capital %14.63.6 401.6%  
Exports to sales %74.524.5 303.7%   
Imports to sales %24.810.2 243.3%   
Exports (fob) Rs m4,4411,264 351.4%   
Imports (cif) Rs m1,477525 281.5%   
Fx inflow Rs m5,2981,539 344.2%   
Fx outflow Rs m1,772942 188.1%   
Net fx Rs m3,525597 590.3%   
CASH FLOW
From Operations Rs m1,274599 212.6%  
From Investments Rs m-1,204-438 275.0%  
From Financial Activity Rs m-196-303 64.8%  
Net Cashflow Rs m-126-141 89.4%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.6 50.0%  
FIIs % 9.6 1.3 738.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 23.6 38.6%  
Shareholders   42,599 10,259 415.2%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   J.B.CHEMICALS  SUVEN LIFE  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 118 Points Higher; Realty and Banking Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours of trade and ended the day marginally higher.

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS